Generics & Biosimilars | Association for Accessible Medicines
Generic Prescription Drugs - Your Health. Our Commitment. #Take with Confidence
  • NAFTA 2.0: Obstacles to More Affordable Medicines for Americans
    NAFTA 2.0: Obstacles to More Affordable Medicines
    The U.S.-Mexico-Canada Agreement (USMCA) or "NAFTA 2.0" contains obstacles to more affordable meds for Americans. There is still time to #FixUSMCA to put America’s patient first!
  • ""
    Failure to Launch
    Although 20 biosimilars have been approved by the FDA in the U.S., only seven are currently commercially available. Learn how patent abuse blocks access to biosimilars for America's patients.
  • ""
    American Patients: Tell Congress to Fix the USMCA
    AAM’s Jonathan Kimball urges Americans to tell their member of Congress to stand up for patients and fix the USMCA trade agreement (NAFTA 2.0).
  • ""
    AAM Membership
    AAM members gain invaluable access to resources, advocacy support and industry meetings and conferences.
  • ""
    Join Me + Get Informed
    Don't miss the keynote speaker at GRx+Biosims 2019, former commissioner of the U.S. Food and Drug Administration, Scott Gottlieb, M.D.
  • Take with Confidence
    Generic Drugs: Take with Confidence
    According to the FDA, “Generic medications are just as safe and effective as their brand-name counterparts, and often cost less.”
  • 2019 AAM Access & Savings report - pills image
    AAM's 2019 Access & Savings in the U.S. Report
    The quality and affordability of generic medicines makes possible greater access, adherence and improved health for millions of patients across the United States.

Recent Updates

Jul 19, 2019 | Erica Klinger
AAM's Ashlee Koonce Shares New Exhibitor Opportunities at GRx+Biosims 2019
Jul 19, 2019 | Erica Klinger
Dive Deeper into the Science and Regulatory Track at GRx+Biosims 2019
Jul 19, 2019 | Erica Klinger
AAM's Christine Simmon Talks About Biosimilar Programming at GRx+Biosims 2019

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.